Newly approved monkeypox vaccine by Japan’s KM Biologics sees immediate overseas demand

FAN Editor

Japanese pharmaceuticals company KM Biologics Co has already seen overseas interest in its monkeypox vaccine which was recently approved by domestic regulators.

KM Biologics, a unit of candy maker Meiji Holdings Co, has had “several inquiries from overseas” a company official told Reuters on Wednesday, declining to comment on any export plan for the shot.

Japan’s health ministry on Tuesday approved the company’s freeze-dried smallpox vaccine LC16 KMB for use against monkeypox, after an experts panel recommended the move last week.

Japan has had only two confirmed cases of monkeypox during the current global outbreak.

MONKEYPOX: WHAT YOU MUST KNOW ABOUT THE VIRUS — AND HOW TO PROTECT YOURSELF

Based in the southern prefecture of Kumamoto, KM Biologics mainly produces vaccines for humans and veterinary use. It has an inactivated COVID-19 shot currently in development.

Free America Network Articles

Leave a Reply

Next Post

Republican lawmaker aims to force Dem states to allow fracking: 'Threatening America’s energy independence'

FIRST ON FOX: Rep. Claudia Tenney, R-N.Y., unveiled a bill Wednesday seeking to force states to allow hydraulic fracturing by tying federal funds to the method of fossil fuel extraction. States with statewide bans on fracking would be barred from receiving any funds from the Energy Efficiency and Conservation Block […]